caryophyllene and Helicobacter-Infections

This 8-week, randomized double-blind, placebo-controlled trial categorized subjects into a β-caryophyllene group (33 patients who received 126 mg/day of β-caryophyllene) and a placebo group (33 patients who received a placebo preparation). The inflammation level of. Complete eradication was not observed in either group. Moreover, there was no significant change in the UBT and updated Sydney score. On the other hand, the β-caryophyllene group showed significant improvement in nausea (p=0.025) and epigastric pain (p=0.018), as well as a decrease in the serum IL-1β levels (p=0.038).. β-caryophyllene improves dyspepsia symptoms and can be considered a useful supplementary treatment for gastrointestinal disease.

Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Breath Tests; Double-Blind Method; Drug Administration Schedule; Dyspepsia; Female; Gastroscopy; Helicobacter Infections; Humans; Interleukin-1beta; Interleukin-6; Male; Middle Aged; Placebo Effect; Polycyclic Sesquiterpenes; Stomach; Treatment Outcome; Tumor Necrosis Factor-alpha

The human specific bacterial pathogen

Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Bacterial Proteins; Female; Gerbillinae; Helicobacter Infections; Helicobacter pylori; Humans; In Vitro Techniques; Male; Polycyclic Sesquiterpenes; Stomach Neoplasms; Virulence Factors

New antibacterial treatments against

Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Helicobacter Infections; Helicobacter pylori; Male; Mice; Mice, Inbred C57BL; Plant Extracts; Polycyclic Sesquiterpenes; Syzygium